Oxidativer Stress & Kardiovaskuläre Erkrankungen

Produktname

MDA-oxLDL ELISA

Enzyme Immunoassay for the quantitative determination of Malondialdehyd oxidized Low-Density-Lipoprotein (MDA-oxLDL) in human serum and plasma

Kat-Nr.BI-20022
Bereich0 – 10 µg/ml
Sensitivität0.05 µg/ml (STD2 0.6 µg/ml)
Inkubationszeit3.5 hours
Probenmenge20 µl
Probentyp

Serum, EDTA-, citrate, heparin plasma

Probenvorbereitung

Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 4 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Referenzwerte

Median = 1.0 μg/ml (n = 70)

Spezies

Human

Tests96
MethodeELISA
Anwendung

Intended use: Research use only.

Oxidatively modified lipoproteins (oxLDLs) play an important role in the progression of atherosclerosis and coronary artery disease. Low-density lipoprotein (LDL), the main carrier of plasma cholesterol, consists of a hydrophobic core and a surface monolayer of polar lipids and Apolipoprotein-B (ApoB). Oxidative stress and the consequent formation of free radicals lead to the peroxidation of ApoB. Malondialdehyde (MDA) has been identified as one of the major lipid peroxidation products of LDL, thus playing an important role in the LDL oxidation. The Biomedica MDA-oxLDL ELISA specifically detects MDA-modified Apo B in human serum and plasma.

Intended applications:

Cardiovascular Disease - atherosclerosis, coronary artery disease, myocardial infarction

Produktinformation

Zurück zur Übersicht